Research programme: anticancer therapeutics - Ranok Therapeutics
Latest Information Update: 03 Sep 2021
At a glance
- Originator Ranok Therapeutics
- Class Antineoplastics
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer